Madrigal Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Centene (CNC), Zimmer Biomet Holdings (ZBH) and Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)
B. Riley Securities: Maintaining the Madrigal Pharmaceuticals (MDGL.US) rating, adjusted from neutral to neutral, and adjusted the target price from $270.00 to $200.00.
Madrigal Pharmaceuticals Analyst Ratings
B. Riley Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $200
Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Start for Rezdiffra
Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL) and Warby Parker (WRBY)
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating
HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $390
Citi: Maintains Madrigal Pharmaceuticals (MDGL.US) rating, adjusted from buy to buy rating, and adjusted the target price from $389.00 to $382.00.
Citigroup Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $382
JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $381
J.P. Morgan Securities: Maintaining the Madrigal Pharmaceuticals (MDGL.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $397.00 to $381.00.
Madrigal Pharmaceuticals Analyst Ratings
Madrigal Pharmaceuticals: Strong Buy Rating Amidst Rapid Growth and Strategic Initiatives
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)
Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch and Solid Financials
United Healthcare's Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Rating
No Data